Ligand-Receptor Interactions of Galectin-9 and VISTA Suppress Human T Lymphocyte Cytotoxic Activity

  • Inna M Yasinska
  • N Helge Meyer
  • Stephanie Schlichtner
  • Rohanah Hussain
  • Giuliano Siligardi
  • Maxwell Casely-Hayford
  • Walter Fiedler
  • Jasmin Wellbrock
  • Cloe Desmet
  • Luigi Calzolai
  • Luca Varani
  • Steffen M Berger
  • Ulrike Raap
  • Bernhard F Gibbs
  • Elizaveta Fasler-Kan
  • Vadim V Sumbayev

Related Research units

Abstract

Acute myeloid leukemia (AML), a blood/bone marrow cancer, is a severe and often fatal malignancy. AML cells are capable of impairing the anti-cancer activities of cytotoxic lymphoid cells. This includes the inactivation of natural killer (NK) cells and killing of T lymphocytes. Here we report for the first time that V-domain Ig-containing suppressor of T cell activation (VISTA), a protein expressed by T cells, recognizes galectin-9 secreted by AML cells as a ligand. Importantly, we found that soluble VISTA released by AML cells enhances the effect of galectin-9, most likely by forming multiprotein complexes on the surface of T cells and possibly creating a molecular barrier. These events cause changes in the plasma membrane potential of T cells leading to activation of granzyme B inside cytotoxic T cells, resulting in apoptosis.

Bibliographical data

Original languageEnglish
ISSN1664-3224
DOIs
Publication statusPublished - 20.11.2020
PubMed 33329552